Navigation Links
PharmSource Releases White Paper on Role of U.S. Foreign Corrupt Practices Act (FCPA) in the Bio/Pharma Industry
Date:7/8/2009

PharmSource Information Services, Inc. announces the publication of a new white paper - "The U.S. Foreign Corrupt Practices Act (FCPA): How to Minimize Your Risk." This incisive resource provides guidelines on how to establish a strong FCPA compliance program that minimizes corruption risk for companies doing business throughout the world. "The U.S. Foreign Corrupt Practices Act (FCPA): How to Minimize Your Risk" is valued at $495, but will be offered as a free download for a limited time only, from July 8 through July 21, 2009 at www.pharmsource.com/white-paper.

Fairfax, Va. (PRWEB) July 8, 2009 -- PharmSource Information Services, Inc., a respected provider of business intelligence on contract drug development and manufacture, is pleased to announce the publication of a new white paper - "The U.S. Foreign Corrupt Practices Act (FCPA): How to Minimize Your Risk." This incisive resource provides guidelines on how to establish a strong FCPA compliance program that minimizes corruption risk for companies doing business throughout the world.

"The U.S. Foreign Corrupt Practices Act (FCPA): How to Minimize Your Risk" is valued at $495, but will be offered as a free download for a limited time only, from July 8 through July 21, 2009 at www.pharmsource.com/white-paper. This proprietary white paper includes detailed information on:

 
  • Industry-specific implications of current FCPA regulations.
  • Essential elements of a strong FCPA compliance program for those in the bio/pharma industry.
  • Comprehensive steps to implement a solid FCPA compliance program.
  • Enforcement of anti-corruption business practices in emerging markets.
  • Mechanisms to avoid compliance pitfalls despite global and economic challenges.

"This report provides priceless strategic insights on FCPA compliance programs, which could save bio/pharma companies millions of dollars in fines and losses due to an unintended corruption scandal," advises PharmSource founder and president, Jim Miller.

The U.S. is increasing the number of investigations of FCPA and financial fraud violations, particularly within the pharmaceutical sector. This has been reflected by an increase in enforcement budgets and the employment of additional personnel to improve the frequency with which investigations are conducted. Readers will find this timely publication to be a critical first step in understanding FCPA practices and ensuring the protection afforded by a robust compliance program, especially while conducting business in emerging markets.

"[After all, it is far easier to start a compliance program before commencing work overseas than it is to implement one retroactively, but it is also far more cost-effective to implement and run a compliance program than it is to be involved in any kind of FCPA investigation, which not only is costly but can have devastating effects on a company's reputation and business," comments Leslie McCarthy, director of corporate development at The STEELE Foundation, in the white paper.

If you would like to obtain a copy of "The U.S. Foreign Corrupt Practices Act (FCPA): How to Minimize Your Risk," please contact PharmSource via e-mail at info@pharmsource.com or call 1-703-383-4903 (USA ET).

About PharmSource

PharmSource is a respected provider of business intelligence on contract drug development and manufacture. A premier information resource for both biotechnology/pharmaceutical sourcing executives and contract service providers since 1996, PharmSource has provided organizations involved in contract pharma services with publications, databases, surveys and consulting services. Companies from around the world continually rely on PharmSource's deep industry expertise and analyses to help them make smarter strategic business decisions.

About PharmSource ADVANTAGE

PharmSource ADVANTAGE online service is one of the industry's most respected outsourcing information web portals for serious consumers of information on contract drug development and manufacturing. This strategic resource allows subscribers to receive industry insight and analysis through two regular publications - Bio/Pharmaceutical Outsourcing Report and Emerging Markets Outsourcing Report. It also includes full access to PharmSource's highly regarded database of contract service providers, where subscribers can search for and compare hundreds of companies from around the world that serve the pharma industry.

###

Read the full story at http://www.prweb.com/releases/2009/07/prweb2616754.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. PharmSource Adds New Capabilities to the PharmSource ADVANTAGE Online Service
2. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
3. PharmSource President Moderates Videocast on Outsourcing to Asia at AAPS
4. PharmSource Introduces Proprietary Resource for Identifying New Business Opportunities in Bio/Pharma
5. CEL-SCI Corporation Releases Letter to Shareholders
6. Elsevier Releases Results of Alternative Energy Research Leadership Study Identifying Top 25 Institutions Worldwide
7. A-WIT Technologies Releases World's First Low Cost C Stamp(TM) Based Biotechnology Laboratory in a Box
8. Clontech Laboratories, Inc. Releases the Xfect(TM) and Xfect(TM) Stem Transfection Reagents
9. Nucletron Releases Comprehensive Film-and Volume-Based Planning System for Wide Variety of Brachy Solutions
10. ZyGEM Releases Application Note Showing its DNA Extraction Kits Rapidly Produce High Yields of Quality DNA
11. Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Jan. 18, 2017 The global biotechnology ... 92.9 billion by 2025, according to a new ... has been adaptive of the function of outsourcing ... 2002. Among the services outsourced, clinical trial management ... Johnson & Johnson was the first pharmaceutical company ...
(Date:1/19/2017)... -- Acupath Laboratories, Inc., a leading provider of sub-specialized ... Committee that will guide the company,s vision and strategy ... , a 15-year veteran of the anatomic pathology industry, ... Chief Sales Officer .  Prior to joining Acupath ... leadership roles at several leading lab industry organizations including, ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... device-to-computer interconnect using USB or PCI Express, announced the ZEM5310 USB 3.0 FPGA ... FPGA into a compact business-card sized form factor suitable for prototyping, testing, and ...
(Date:1/18/2017)... , Jan. 18, 2017   Boston Biomedical , ... designed to target cancer stemness pathways, will feature data ... napabucasin, at the 2017 ASCO Gastrointestinal Cancers Symposium, held ... . Napabucasin is an orally-administered investigational ... STAT3. i Cancer stem cells (CSCs) possess the ...
Breaking Biology Technology:
(Date:1/3/2017)... Onitor, provider of digital health technology for ... innovative biometric data-driven program designed to aid weight loss ... 2017 Consumer Electronics Show (CES) in Las ... the World Health Organization (WHO), have identified lifestyle risks ... are overweight or obese. WHO also states that more ...
(Date:12/22/2016)... SuperCom (NASDAQ:   SPCB ... Safety, HealthCare, and Finance sectors announced today that Leaders in Community ... and deploy a community-based supportive services program to reduce recidivism in ... expanding its presence in the state. ... This new program, which is expected to commence ...
(Date:12/20/2016)... 20, 2016   Valencell , the leading ... STMicroelectronics (NYSE: STM), a global semiconductor leader ... announced today the launch of a new, highly ... that includes ST,s compact SensorTile turnkey ... biometric sensor system. Together, SensorTile and Benchmark deliver ...
Breaking Biology News(10 mins):